Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1726 to 1740 of 2026 results for nice guidelines

  1. Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment (HTG746)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.

  2. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  3. Natural Cycles for monitoring fertility (MIB244)

    NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .

  4. Management and organisational approaches to safe staffing

    Discontinued Reference number: GID-SGWAVE0761

  5. Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)

    Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.

  6. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

  7. Community nursing care settings

    Discontinued Reference number: GID-SGWAVE0700

  8. Accident and emergency departments

    Discontinued Reference number: GID-SGWAVE0762

  9. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

  10. The EOS 2D/3D imaging system (HTG274)

    Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.

  11. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  12. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

  13. Fruquintinib for previously treated metastatic colorectal cancer (TA1079)

    Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.

  14. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

  15. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.